Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar 15:2022:3208780.
doi: 10.1155/2022/3208780. eCollection 2022.

Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer

Li Zhang  1 , Yuan He  1 , ChengFeng Yi  1 , Mei Huang  1
Affiliations
Meta-Analysis

Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer

Li Zhang et al. J Healthc Eng. .

Abstract

Objective: To evaluate the efficacy of recombinant human endostatin combined with gemcitabine and cisplatin in the treatment of non-small-cell lung cancer (NSCLC).

Methods: The databases of Cochrane Library, Embase, ClinicalTrials, PubMed, HowNet, Wanfang, and VIP were searched to collect randomized controlled trials (RCTs) of recombinant human endostatin combined with gemcitabine and cisplatin (experimental group) and gemcitabine combined with cisplatin (control group) for comparative study. The quality of literature was evaluated by bias risk assessment tools and related scales, and then meta-analysis was performed.

Results: A total of 27 RCTs (1646 patients) were included. The results of meta-analysis showed that the effective rate (P < 0.000 01) and benefit rate (P < 0.000 01) of the experimental group were significantly higher than those of the control group, the incidence of leucopenia (P = 0.79), thrombocytopenia (P = 0.39), and gastrointestinal reaction (P = 0.85) were not statistically significant.

Conclusion: The combination of recombinant human endostatin, gemcitabine, and cisplatin can increase the efficacy and safety of NSCLC patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart.
Figure 2
Figure 2
Bar chart of bias risk.
Figure 3
Figure 3
Bias risk diagram.
Figure 4
Figure 4
Inverted funnel plot of effective rate.
Figure 5
Figure 5
Efficient Begg's diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chen L., Zhu X., Li D., Cai X. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer. Journal of BUON . 2020;25(6):2643–2649. - PubMed
    1. Zhang S.-L., Han C.-B., Sun L., Huang L.-T., Ma J.-T. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: A pooled analysis. Radiation Oncology . 2020;15(1):p. 205. doi: 10.1186/s13014-020-01646-9. - DOI - PMC - PubMed
    1. Feng L., Wang Z., Jing L., et al. Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: A meta-analysis. World Journal of Surgical Oncology . 2021;19(1):p. 64. doi: 10.1186/s12957-021-02161-1. - DOI - PMC - PubMed
    1. Zhang K., Wang H., Wang Z., et al. Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer: Results from a hospital in the Qinghai-Tibet Plateau. Medicine . 2020;99(49) doi: 10.1097/MD.0000000000021966.e21966 - DOI - PMC - PubMed
    1. Guan L. Endostar rebuilding vascular homeostasis and enhancing chemotherapy efficacy in cervical cancer treatment. OncoTargets and Therapy . 2020;13(13):12811–12827. doi: 10.2147/ott.s277644. - DOI - PMC - PubMed

Publication types

MeSH terms